InVivo Therapeutics Holdings Corp. announced a three-month update for the first subject in the company's ongoing pilot trial of its investigational Neuro-Spinal Scaffold in subjects with acute spinal cord injury. The Neuro-Spinal Scaffold was implanted in the subject on October 14, 2014 at the Barrow Neurological Institute at St.

Joseph's Hospital and Medical Center in Phoenix, AZ by Dr. Nicholas Theodore, Chief of Spinal Surgery. In the time between implantation and the 3-month post-injury assessment, there were no reported serious adverse events associated with the Neuro-Spinal Scaffold and the subject had progressed from a complete AIS A injury to an incomplete AIS C injury with motor, sensory, bowel, and bladder function improvements. Motor improvement from the pre-surgery assessment to the 3-month visit involved the return of active movement of the hip flexors against gravity (allowing for leg to chest motions) and palpable contractions of the knee extensors.

Sensory improvement from the pre-surgery assessment to the 3-month visit involved the bilateral return of sensation to two dermatomes extending down the top of the subject's legs and the S4-S5 dermatome. In addition, the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) exam, the Spinal Cord Independence Measure (SCIM III) exam, and additional assessments of bowel and bladder function demonstrated that between hospital discharge and the 3-month visit, the subject has regained bowel function and improved bladder function. The data from the first subject were obtained and calculated in accordance with the ISNCSCI, the standard examination used to determine motor and sensory impairment and severity of a spinal cord injury.